ODN 2216 is a human-specific TLR9 (toll-like receptor 9) ligand or agonist. ODN 2216 induces high amounts of IFN-α and IFN-β . ODN 2216 induces IFN-α by pDC (plasmacytoid DC) and IL-12 (p40) production by DC (dendritic cells). ODN 2216 stimulates IFN-γ production in peripheral blood mononuclear cells (PBMC), which is indirect and mediated by IFN-α/β. ODN 2216 can activate NK cells and promote IFN-γ production of TCR-triggered CD4 + T cells In Vitro ODN 2216 (6 μg/mL, 9 days) drives Th1 development of naive CD4 T cells. ODN 2216 (2 μM, 15 h) significantly decreased apoptosis of thymic DC. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Apoptosis AnalysisCell Line: Thymic DC, pDC Concentration: 2 μM Incubation Time: 15 h Result: Significantly decreased apoptosis of thymic DC (23.1 ± 0.9%), and naturally induced apoptosis of thymic pDC was not decreased (72.8 ± 2.9%). In Vivo ODN 2216 induces T-cell mediated antitumor immune response in murine vaccination modelsMCE has not independently confirmed the accuracy of these methods. They are for reference only. Form:Solid IC50& Target:TLR9 IL-12